



A Pfizer Company

# SAFETY DATA SHEET

Revision date: 19-Jun-2017

Version: 1.0

Page 1 of 10

## 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

### Product Identifier

**Material Name:** Tobramycin in Sodium Chloride Injection (Hospira, Inc.)

**Trade Name:** Tobramycin Injection

**Chemical Family:** Aminoglycoside

### Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

**Intended Use:** Pharmaceutical product used as antibiotic agent

### Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company  
275 North Field Drive  
Lake Forest, Illinois 60045  
1-800-879-3477

Hospira UK Limited  
Horizon  
Honey Lane  
Hurley  
Maidenhead, SL6 6RJ  
United Kingdom

### Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

### Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

## 2. HAZARDS IDENTIFICATION

### Classification of the Substance or Mixture

#### GHS - Classification

Skin Sensitization: Category 1

Reproductive Toxicity: Category 1A

### Label Elements

**Signal Word:** Danger

**Hazard Statements:** H317 - May cause an allergic skin reaction

H360D - May damage the unborn child

### Precautionary Statements:

P202 - Do not handle until all safety precautions have been read and understood

P261 - Avoid breathing dust/fume/gas/mist/vapors/spray

P280 - Wear protective gloves/protective clothing/eye protection/face protection

P272 - Contaminated work clothing must not be allowed out of the workplace

P302+ P352 - IF ON SKIN: Wash with plenty of soap and water

P308 + P313 - IF exposed or concerned: Get medical attention/advice

P333 + P313 - If skin irritation or rash occurs: Get medical advice/attention

P363 - Wash contaminated clothing before reuse

P405 - Store locked up

P501 - Dispose of contents/container in accordance with all local and national regulations

## SAFETY DATA SHEET

Material Name: Tobramycin in Sodium Chloride Injection  
(Hospira, Inc.)  
Revision date: 19-Jun-2017

Page 2 of 10

Version: 1.0



### Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

### Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

### 3. COMPOSITION / INFORMATION ON INGREDIENTS

#### Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Tobramycin sulfate	49842-07-1	256-499-2	Repr. 1A (H360D) Skin Sens. 1 (H317)	</= 4
Sulfuric acid	7664-93-9	231-639-5	Skin Corr. 1A (H314)	**
SODIUM HYDROXIDE	1310-73-2	215-185-5	Skin Corr. 1A (H314)	**
Sodium chloride	7647-14-5	231-598-3	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Water for injection	7732-18-5	231-791-2	Not Listed	*

#### Additional Information:

\* Proprietary  
\*\* to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases mentioned in this Section, see Section 16

### 4. FIRST AID MEASURES

#### Description of First Aid Measures

##### Eye Contact:

Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

##### Skin Contact:

Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

##### Ingestion:

Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

##### Inhalation:

Remove to fresh air and keep patient at rest. Seek medical attention immediately.

## SAFETY DATA SHEET

Material Name: Tobramycin in Sodium Chloride Injection  
(Hospira, Inc.)  
Revision date: 19-Jun-2017

Page 3 of 10

Version: 1.0

### Most Important Symptoms and Effects, Both Acute and Delayed

<b>Symptoms and Effects of Exposure:</b>	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
<b>Medical Conditions Aggravated by Exposure:</b>	None known

### Indication of the Immediate Medical Attention and Special Treatment Needed

**Notes to Physician:** None

## 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Use carbon dioxide, dry chemical, or water spray.

### Special Hazards Arising from the Substance or Mixture

**Hazardous Combustion Products:** Emits toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, sulfur oxides and other sulfur-containing compounds.

**Fire / Explosion Hazards:** Fine particles (such as dust and mists) may fuel fires/explosions.

### Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

## 6. ACCIDENTAL RELEASE MEASURES

### Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

### Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

### Methods and Material for Containment and Cleaning Up

**Measures for Cleaning / Collecting:** Contain the source of the spill if it is safe to do so. Absorb spills with non-combustible absorbent material and transfer into a labeled container for disposal.

**Additional Consideration for Large Spills:** Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

## 7. HANDLING AND STORAGE

### Precautions for Safe Handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

### Conditions for Safe Storage, Including any Incompatibilities

**Storage Conditions:** Store as directed by product packaging.

**Specific end use(s):** Pharmaceutical drug product

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

### Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

## SAFETY DATA SHEET

Material Name: Tobramycin in Sodium Chloride Injection  
(Hospira, Inc.)  
Revision date: 19-Jun-2017

Page 4 of 10

Version: 1.0

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

#### Tobramycin sulfate

Pfizer OEL TWA-8 Hr: 600µg/m<sup>3</sup>

#### Sulfuric acid

ACGIH Threshold Limit Value (TWA)	0.2 mg/m <sup>3</sup>
Australia STEL	3 mg/m <sup>3</sup>
Australia TWA	1 mg/m <sup>3</sup>
Austria OEL - MAKs	0.1 mg/m <sup>3</sup>
Belgium OEL - TWA	0.2 mg/m <sup>3</sup>
Bulgaria OEL - TWA	0.05 mg/m <sup>3</sup>
Cyprus OEL - TWA	0.05 mg/m <sup>3</sup>
Czech Republic OEL - TWA	1 mg/m <sup>3</sup>
	0.05 mg/m <sup>3</sup>
Denmark OEL - TWA	0.05 mg/m <sup>3</sup>
Estonia OEL - TWA	1 mg/m <sup>3</sup>
Finland OEL - TWA	0.05 mg/m <sup>3</sup>
France OEL - TWA	0.05 mg/m <sup>3</sup>
Germany - TRGS 900 - TWAs	0.1 mg/m <sup>3</sup>
Germany (DFG) - MAK	0.1 mg/m <sup>3</sup>
Greece OEL - TWA	0.05 mg/m <sup>3</sup>
Hungary OEL - TWA	0.05 mg/m <sup>3</sup>
Ireland OEL - TWAs	0.05 ppm
Italy OEL - TWA	0.05 mg/m <sup>3</sup>
Japan - OELs - Ceilings	1 mg/m <sup>3</sup>
Latvia OEL - TWA	0.05 mg/m <sup>3</sup>
Lithuania OEL - TWA	0.05 mg/m <sup>3</sup>
Luxembourg OEL - TWA	0.05 mg/m <sup>3</sup>
Malta OEL - TWA	0.05 mg/m <sup>3</sup>
Netherlands OEL - TWA	0.05 mg/m <sup>3</sup>
OSHA - Final PELs - TWAs:	1 mg/m <sup>3</sup>
Poland OEL - TWA	0.05 mg/m <sup>3</sup>
Portugal OEL - TWA	0.05 mg/m <sup>3</sup>
Romania OEL - TWA	0.05 mg/m <sup>3</sup>
Slovakia OEL - TWA	0.1 mg/m <sup>3</sup>
Slovenia OEL - TWA	0.05 mg/m <sup>3</sup>
Spain OEL - TWA	0.05 mg/m <sup>3</sup>
Sweden OEL - TWAs	0.1 mg/m <sup>3</sup>
Switzerland OEL - TWAs	0.1 mg/m <sup>3</sup>
Vietnam OEL - TWAs	1 mg/m <sup>3</sup>

#### SODIUM HYDROXIDE

ACGIH Ceiling Threshold Limit:	2 mg/m <sup>3</sup>
Australia PEAK	2 mg/m <sup>3</sup>
Austria OEL - MAKs	2 mg/m <sup>3</sup>
Bulgaria OEL - TWA	2.0 mg/m <sup>3</sup>
Czech Republic OEL - TWA	1 mg/m <sup>3</sup>
Estonia OEL - TWA	1 mg/m <sup>3</sup>
France OEL - TWA	2 mg/m <sup>3</sup>
Greece OEL - TWA	2 mg/m <sup>3</sup>
Hungary OEL - TWA	2 mg/m <sup>3</sup>

## SAFETY DATA SHEET

Material Name: Tobramycin in Sodium Chloride Injection  
(Hospira, Inc.)  
Revision date: 19-Jun-2017

Page 5 of 10

Version: 1.0

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Japan - OELs - Ceilings	2 mg/m <sup>3</sup>
Latvia OEL - TWA	0.5 mg/m <sup>3</sup>
OSHA - Final PELs - TWAs:	2 mg/m <sup>3</sup>
Poland OEL - TWA	0.5 mg/m <sup>3</sup>
Slovakia OEL - TWA	2 mg/m <sup>3</sup>
Slovenia OEL - TWA	2 mg/m <sup>3</sup>
Sweden OEL - TWAs	1 mg/m <sup>3</sup>
Switzerland OEL - TWAs	2 mg/m <sup>3</sup>

#### Sodium chloride

Latvia OEL - TWA	5 mg/m <sup>3</sup>
Lithuania OEL - TWA	5 mg/m <sup>3</sup>

#### Sodium chloride

Pfizer Occupational Exposure Band (OEB): OEB 1 (control exposure to the range of 1000ug/m<sup>3</sup> to 3000ug/m<sup>3</sup>)

#### Exposure Controls

##### Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

##### Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

##### Hands:

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

##### Eyes:

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

##### Skin:

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

##### Respiratory protection:

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

### 9. PHYSICAL AND CHEMICAL PROPERTIES

#### Physical State:

Sterile solution

#### Color:

Clear, colorless

#### Odor:

No data available.

#### Odor Threshold:

No data available.

#### Molecular Formula:

Mixture

#### Molecular Weight:

Mixture

#### Solvent Solubility:

No data available

#### Water Solubility:

No data available

#### pH:

3.0-6.5

#### Melting/Freezing Point (°C):

No data available

#### Boiling Point (°C):

No data available.

## SAFETY DATA SHEET

Material Name: Tobramycin in Sodium Chloride Injection  
(Hospira, Inc.)  
Revision date: 19-Jun-2017

Page 6 of 10

Version: 1.0

### 9. PHYSICAL AND CHEMICAL PROPERTIES

Partition Coefficient: (Method, pH, Endpoint, Value)

**Water for injection**

No data available

**Sulfuric acid**

No data available

**SODIUM HYDROXIDE**

No data available

**Tobramycin sulfate**

No data available

**Sodium chloride**

No data available

**Decomposition Temperature (°C):** No data available.

**Evaporation Rate (Gram/s):** No data available

**Vapor Pressure (kPa):** No data available

**Vapor Density (g/ml):** No data available

**Relative Density:** No data available

**Viscosity:** No data available

**Flammability:**

**Autoignition Temperature (Solid) (°C):** No data available

**Flammability (Solids):** No data available

**Flash Point (Liquid) (°C):** No data available

**Upper Explosive Limits (Liquid) (% by Vol.):** No data available

**Lower Explosive Limits (Liquid) (% by Vol.):** No data available

**Polymerization:** Will not occur

### 10. STABILITY AND REACTIVITY

**Reactivity:** No data available

**Chemical Stability:** Stable under normal conditions of use.

**Possibility of Hazardous Reactions**

**Oxidizing Properties:** No data available

**Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions.

**Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

**Hazardous Decomposition Products:** No data available

### 11. TOXICOLOGICAL INFORMATION

**Information on Toxicological Effects**

**General Information:** The information included in this section describes the potential hazards of the individual ingredients.

**Short Term:** May cause eye and skin irritation (based on components) .

**Long Term:** Repeat-dose studies in animals have shown a potential to cause adverse effects on kidneys.

**Known Clinical Effects:** May cause effects similar to those seen in clinical use including transient diarrhea, nausea and abdominal pain. Adverse effects most commonly reported in clinical use include effects on hearing, nausea, vomiting, and vertigo (vestibular ototoxicity), nervous system/brain toxicity (neurotoxicity), and kidney toxicity (nephrotoxicity). May cause adverse effects on the developing fetus. Serious allergic reactions, including anaphylaxis, have been reported.

**Acute Toxicity: (Species, Route, End Point, Dose)**

## SAFETY DATA SHEET

Material Name: Tobramycin in Sodium Chloride Injection  
(Hospira, Inc.)  
Revision date: 19-Jun-2017

Page 7 of 10

Version: 1.0

### 11. TOXICOLOGICAL INFORMATION

#### Sulfuric acid

Rat Oral LD50 2140 mg/kg

#### Tobramycin sulfate

Rat Oral LD50 > 7500 mg/kg  
Rat Para-periosteal LD50 133mg/kg

#### Sodium chloride

Rat Oral LD50 3000 mg/kg  
Mouse Oral LD50 4000 mg/kg

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

#### Irritation / Sensitization: (Study Type, Species, Severity)

##### Sulfuric acid

Eye Irritation Rabbit Severe

##### Tobramycin sulfate

Eye Irritation Rabbit Slight  
Skin Irritation Rabbit Slight

##### Sodium chloride

Eye Irritation Rabbit Moderate  
Skin Irritation Rabbit Mild

#### Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

##### Tobramycin sulfate

Reproductive & Fertility Rat Subcutaneous 100 mg/kg/day NOAEL No effects at maximum dose  
Embryo / Fetal Development Rat Subcutaneous 100 mg/kg/day NOAEL No effects at maximum dose  
Embryo / Fetal Development Rabbit Subcutaneous 20 mg/kg/day LOAEL Maternal Toxicity, Fetal mortality

**Carcinogen Status:** None of the components present in this material at concentrations equal to or greater than 0.1% are listed by IARC, NTP, OSHA, or ACGIH as a carcinogen.

##### Sulfuric acid

**IARC:** Group 1 (Carcinogenic to Humans)

### 12. ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

**Toxicity:** No data available

**Persistence and Degradability:** No data available

## SAFETY DATA SHEET

Material Name: Tobramycin in Sodium Chloride Injection  
(Hospira, Inc.)  
Revision date: 19-Jun-2017

Page 8 of 10

Version: 1.0

**Bio-accumulative Potential:** No data available

**Mobility in Soil:** No data available

### 13. DISPOSAL CONSIDERATIONS

**Waste Treatment Methods:** Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

### 14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

### 15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

#### Tobramycin sulfate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	developmental toxicity 7/1/1990
Australia (AICS):	Present
EU EINECS/ELINCS List	256-499-2

#### Sulfuric acid

CERCLA/SARA 313 Emission reporting	1.0 %
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	1000 lb 454 kg
CERCLA/SARA - Section 302 Extremely Hazardous TPQs	1000 lb
CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs	1000 lb
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present



## SAFETY DATA SHEET

Material Name: Tobramycin in Sodium Chloride Injection  
(Hospira, Inc.)  
Revision date: 19-Jun-2017

Page 9 of 10

Version: 1.0

### 15. REGULATORY INFORMATION

Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 6
EU EINECS/ELINCS List	231-639-5

#### Water for injection

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	231-791-2

#### SODIUM HYDROXIDE

CERCLA/SARA 313 Emission reporting	Not Listed
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	1000 lb 454 kg
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 5 Schedule 6
EU EINECS/ELINCS List	215-185-5

#### Sodium chloride

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-598-3

### 16. OTHER INFORMATION

#### Text of CLP/GHS Classification abbreviations mentioned in Section 3

Skin corrosion/irritation-Cat.1A; H314 - Causes severe skin burns and eye damage  
Sensitization, skin-Cat.1; H317 - May cause an allergic skin reaction  
Reproductive toxicity-Cat.1A; H360D - May damage the unborn child

**Data Sources:** Publicly available toxicity information. Safety data sheets for individual ingredients. Pfizer proprietary drug development information.

**Reasons for Revision:** New data sheet.

**Revision date:** 19-Jun-2017

**Prepared by:** Product Stewardship Hazard Communication  
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

## SAFETY DATA SHEET

Material Name: Tobramycin in Sodium Chloride Injection  
(Hospira, Inc.)  
Revision date: 19-Jun-2017

Page 10 of 10

Version: 1.0

---

End of Safety Data Sheet